Cita APA (7a ed.)
Roberts, M. S., Anstine, L. J., Finke, V. S., Bryson, B. L., Webb, B. M., Weber-Bonk, K. L., . . . Keri, R. A. (2020). KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene. Breast Cancer Research, 22(1), 1-15.
Cita Chicago Style (17a ed.)
Roberts, Melyssa S., Lindsey J. Anstine, Viviane S. Finke, Benjamin L. Bryson, Bryan M. Webb, Kristen L. Weber-Bonk, Darcie D. Seachrist, Parth R. Majmudar, y Ruth A. Keri. "KLF4 Defines the Efficacy of the Epidermal Growth Factor Receptor Inhibitor, Erlotinib, in Triple-negative Breast Cancer Cells by Repressing the EGFR Gene." Breast Cancer Research 22, no. 1 (2020): 1-15.
Cita MLA (9a ed.)
Roberts, Melyssa S., et al. "KLF4 Defines the Efficacy of the Epidermal Growth Factor Receptor Inhibitor, Erlotinib, in Triple-negative Breast Cancer Cells by Repressing the EGFR Gene." Breast Cancer Research, vol. 22, no. 1, 2020, pp. 1-15.
Precaución: Estas citas no son 100% exactas.